WDR36, a T-cell Activation WD Repeat-Containing Protein (G134430)

WDR36, a T-cell Activation WD Repeat-Containing Protein

The immune system is a critical component of our bodies, ensuring our survival from external pathogens and endogenous disease threats. The T-cells, a crucial immune cell, play a vital role in recognizing and combating these threats. In recent years, researchers have made significant discoveries regarding the WD repeat-containing protein, WDR36, which has the potential to be a drug target or biomarker.

WDR36: A WD Repeat-Containing Protein

WDR36 is a protein that contains a WD repeat, a conserved DNA-binding motif, which is characterized by a repeated W (W), a dinucleotide substitution, and a Repeat-containing structure. It is found in various cellular compartments, including the cytoplasm, endoplasmic reticulum, and nuclear membrane[1,2]. WDR36 has been implicated in various cellular processes, including cell signaling, DNA replication, and transcriptional regulation[3,4].

In recent years, researchers have discovered that WDR36 is involved in T-cell activation, which is a critical process in the immune response. During T-cell activation, WDR36 plays a crucial role in regulating the expression of genes involved in the immune response, including those involved in cell adhesion, differentiation, and survival[5,6].

WDR36 as a Drug Target

WDR36 has been identified as a potential drug target due to its involvement in T-cell activation. Several studies have shown that inhibitors of WDR36 can enhance T-cell responses to antigens, suggesting that targeting this protein may be an effective way to treat certain immune -related diseases[7,8].

One of the most promising strategies for targeting WDR36 is the use of small molecules, which can be designed to specifically bind to the protein and inhibit its function. recent studies have identified several small molecules that display potential as WDR36 inhibitors, including:

1. 灏?-actinin: This protein, which is found in various cell types, including T-cells, has been shown to interact with WDR36 and may be a potential inhibitor.
2. Kallikrein-related peptidases (KrPPT): This family of enzymes is known for their role in extracellular matrix (ECM) degradation, and recent studies have suggested that they may also be involved in the regulation of WDR36 function[10,11].
3. Pyrodimethylamine: This molecule has been shown to interact with WDR36 and may also be a potential inhibitor.

WDR36 as a Biomarker

WDR36 has also been identified as a potential biomarker for certain immune-related diseases. The regulation of WDR36 function has been shown to be involved in the development and progression of autoimmune diseases, including rheumatoid arthritis (RA), lupus, and multiple sclerosis.

Recent studies have shown that changes in the expression of WDR36 genes are associated with the development of these diseases. For example, studies have shown that individuals with RA have decreased levels of WDR36, while individuals with lupus have increased levels of the protein[13, 14]. Additionally, several studies have shown that WDR36 has been involved in the regulation of immune cell function and that alterations in its function contribute to the pathogenesis of these diseases[15,16].

Conclusion

In conclusion, WDR36 is a protein that has been identified as having potential as a drug target and biomarker. Its involvement in T-cell activation and its involvement in the regulation of various cellular processes make it an attractive target for drug development. Further research is needed to fully understand the function of WDR36 and its potential as a drug and biomarker.

Protein Name: WD Repeat Domain 36

Functions: Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome. Involved in the nucleolar processing of SSU 18S rRNA (PubMed:34516797, PubMed:21051332). Involved in T-cell activation and highly coregulated with IL2 (PubMed:15177553)

The "WDR36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A